EXHIBIT 99.1

[AETHLON MEDICAL, INC. LOGO]


FOR IMMEDIATE RELEASE: Company Contact:
James A. Joyce
Chairman, CEO
619.368.2000
jj@aethlonmedical.com
---------------------


AETHLON MEDICAL COMPLETES $673,000 PRIVATE PLACEMENT AND
SECURES $6 MILLION EQUITY FUNDING COMMITMENT

San Diego, CA, June 9, 2004 - Aethlon Medical, Inc. (OTCBB:AEMD) announced today
that it has completed a $673,000 private placement of common stock with
accredited investors, including Fusion Capital Fund II, LLC, a Chicago based
institutional investor. Aethlon also announced that it has entered into a common
stock purchase agreement with Fusion Capital, whereby Fusion Capital has
committed to buy an additional $6.0 million of Aethlon's common stock. The funds
from both of these transactions will be utilized to accelerate the development
and commercialization of Aethlon's treatment countermeasures against Biological
Weapons, HIV/AIDS, and Hepatitis-C.

Under terms of the $6.0 million transaction with Fusion Capital, Fusion has
agreed to purchase from the Company up to $6.0 million of Aethlon's common stock
over a 30-month period. Specifically, after the Securities & Exchange Commission
has declared effective a registration statement, each month Aethlon has the
right to sell to Fusion Capital $200,000 of its common stock at a purchase price
based upon the market price of Aethlon's common stock on the date of each sale
without any fixed discount to the market price. At Aethlon's sole option, Fusion
Capital can be required to purchase lesser or greater amounts of common stock
each month up to $6.0 million in the aggregate. The Company has the right to
control the timing and the amount of stock sold to Fusion Capital. Aethlon also
has the right to terminate the agreement at any time without any additional
cost. Fusion Capital has agreed not to engage in any direct or indirect short
selling or hedging of the common stock in any manner whatsoever.

"The proceeds from the private placement will advance our clinical strategies
for commercializing our countermeasures against Biological Weapons, as well as
our treatments for HIV/AIDS and Hepatitis-C," commented James A. Joyce, CEO of
Aethlon. Mr. Joyce continued, "The additional $6 million funding commitment from
Fusion Capital provides us with an increased level of financial security, as
well as a flexible means to access capital resources at market prices. We are
truly grateful to have an investment partner that shares our global vision for
treating infectious disease."

A more detailed description of both transactions is set forth in Aethlon's
report on Form 8-K, to be filed today with the SEC.



About Fusion Capital

Fusion Capital Fund II, LLC is a broad based investment fund, based in Chicago,
Illinois. Fusion Capital makes a wide range of investments ranging from special
situation financing to long-term strategic capital.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices that
rapidly reduce the presence of infectious disease and toxins in the body.
Aethlon has published compelling human blood studies of the HemopurifierTM to
treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it
is developing pathogen filtration devices to treat infectious agents used in
biological warfare and terrorism. The Hemopurifier is a proprietary platform
technology that converges the established scientific principles of affinity
chromatography and hemodialysis as a means to augment the immune response of
clearing viruses and toxins from the blood before cell and organ infection can
occur. On March 4, 2004, Aethlon announced a cooperative agreement with the
National Center for Biodefense (NCBD) at George Mason University. Under the
agreement, Aethlon and the NCBD will collaborate to develop pathogen and toxin
filtration devices designed to protect the lives of U.S. Military personnel
exposed to infectious agents as a result of biological warfare. For additional
information, visit the company's Web site at WWW.AETHLONMEDICAL.COM.


CERTAIN OF THE STATEMENTS HEREIN MAY BE FORWARD-LOOKING AND INVOLVE RISKS AND
UNCERTAINTIES. SUCH FORWARD-LOOKING STATEMENTS INVOLVE ASSUMPTIONS, KNOWN AND
UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL
RESULTS, PERFORMANCE OR ACHIEVEMENTS OF AETHLON MEDICAL, INC TO BE MATERIALLY
DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE, OR ACHIEVEMENTS EXPRESSED OR
IMPLIED BY THE FORWARD-LOOKING STATEMENTS. SUCH POTENTIAL RISKS AND
UNCERTAINTIES INCLUDE, WITHOUT LIMITATION, THE COMPANY'S ABILITY TO RAISE
CAPITAL WHEN NEEDED, THE COMPANY'S ABILITY TO COMPLETE THE DEVELOPMENT OF ITS
PLANNED PRODUCTS, THE ABILITY OF THE COMPANY TO OBTAIN FDA AND OTHER REGULATORY
APPROVALS PERMITTING THE SALE OF ITS PRODUCTS, THE COMPANY'S ABILITY TO
MANUFACTURE ITS PRODUCTS AND PROVIDE ITS SERVICES, THE IMPACT OF GOVERNMENT
REGULATIONS, PATENT PROTECTION ON THE COMPANY'S PROPRIETARY TECHNOLOGY, PRODUCT
LIABILITY EXPOSURE, UNCERTAINTY OF MARKET ACCEPTANCE, COMPETITION, TECHNOLOGICAL
CHANGE, AND OTHER RISK FACTORS. IN SUCH INSTANCES, ACTUAL RESULTS COULD DIFFER
MATERIALLY AS A RESULT OF A VARIETY OF FACTORS, INCLUDING THE RISKS ASSOCIATED
WITH THE EFFECT OF CHANGING ECONOMIC CONDITIONS AND OTHER RISK FACTORS DETAILED
IN THE COMPANY'S SECURITIES AND EXCHANGE COMMISSION FILINGS.